Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL
Status:
Completed
Trial end date:
2017-02-02
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter phase II trial designed to evaluate the safety and
activity of the combination of Bendamustine, Lenalidomide and Rituximab (R2-B) in patients
with first relapsed/refractory mantle cell lymphoma (MCL) and the efficacy and safety of a
maintenance treatment with Lenalidomide for 18 months from the end of R2-B (from month 7 to
24) for those responding to the induction.